Sensus Healthcare to Present at COVID-19 Webinar Hosted by Maxim Group on July 16th
BOCA RATON, Fla., July 13, 2020 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, announced today that Joe Sardano, Sensus’ chief executive officer has been invited to present at the Re-Engaging Medical Practices in an Era of COVID-19 webinar, presented by Maxim Group and M-Vest on Thursday, July 16, 2020.
Sensus will participate in a panel discussion on Re-Engaging Medical Practices in an Era of COVID-19. As the country slowly begins to re-open, information is imperative. How and when will medical practices re-open, and to what extent? Will pent-up demand recoup some of the lost revenue? What are doctors observing as they re-engage with patients? Does commercialization pick up where it left off? How are companies adjusting their commercialization strategies and practices during this time? What does access to capital look like in a re-opening world? This conference intends to explore these questions and more, with insights from management, engaging Q&A, and informative panel discussions.
To access the panel discussion, please
Webinar Details:
Date and Time: Thursday, July 16, 11:00 a.m. Eastern time (8:00 a.m. Pacific)
About Sensus Healthcare
Sensus Healthcare, Inc. is a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for both oncological and non-oncological conditions. The Sculptura™ modulated robotic brachytherapy radiation oncology system provides targeted directional anisotropic radiation therapy (ART) and brachytherapy utilizing our proprietary, state-of-the-art 3D Beam Sculpting™ to treat patients undergoing cancer treatment during surgery, or at the tumor site, fast and efficiently. Sensus also offers its proprietary low-energy X-ray technology known as superficial radiation therapy (SRT), which is the culmination of more than a decade of research and development, to treat non-melanoma skin cancers and keloids with its SRT-100™, SRT-100+™ and SRT-100 Vision™ systems. With its portfolio of innovative medical device products, Sensus provides revolutionary treatment options to enhance the quality of life of patients around the world.
For more information, visit .
Contact:
LHA Investor Relations
Kim Sutton Golodetz
212-838-3777
